ECSP12012176A - Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis - Google Patents

Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis

Info

Publication number
ECSP12012176A
ECSP12012176A ECSP12012176A ECSP12012176A EC SP12012176 A ECSP12012176 A EC SP12012176A EC SP12012176 A ECSP12012176 A EC SP12012176A EC SP12012176 A ECSP12012176 A EC SP12012176A
Authority
EC
Ecuador
Prior art keywords
gestagens
aromatase
endometriosis
inhibitors
releases
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Harri Jukarainen
Arto Pakkalin
Rudolf Knauthe
Heinz Schmitz
Christine Talling
Henriikka Korolainen
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44021822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012176(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of ECSP12012176A publication Critical patent/ECSP12012176A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ECSP12012176 2010-03-31 2012-09-24 Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis ECSP12012176A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102010003494A DE102010003494A1 (de) 2010-03-31 2010-03-31 Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose

Publications (1)

Publication Number Publication Date
ECSP12012176A true ECSP12012176A (es) 2012-10-30

Family

ID=44021822

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012176 ECSP12012176A (es) 2010-03-31 2012-09-24 Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis

Country Status (41)

Country Link
US (2) US20130131027A1 (enExample)
EP (1) EP2552404B1 (enExample)
JP (2) JP6012048B2 (enExample)
KR (1) KR20130010047A (enExample)
CN (1) CN103002873B (enExample)
AR (1) AR080861A1 (enExample)
AU (1) AU2011234587B2 (enExample)
BR (1) BR112012024739A2 (enExample)
CA (1) CA2794790A1 (enExample)
CL (1) CL2012002722A1 (enExample)
CO (1) CO6630125A2 (enExample)
CR (1) CR20120493A (enExample)
CU (1) CU20120145A7 (enExample)
CY (1) CY1116187T1 (enExample)
DE (1) DE102010003494A1 (enExample)
DK (1) DK2552404T3 (enExample)
DO (1) DOP2012000255A (enExample)
EA (1) EA025582B1 (enExample)
EC (1) ECSP12012176A (enExample)
ES (1) ES2533101T3 (enExample)
GT (1) GT201200267A (enExample)
HR (1) HRP20150294T1 (enExample)
IL (1) IL222056A (enExample)
MA (1) MA34099B1 (enExample)
ME (1) ME02159B (enExample)
MX (1) MX2012011329A (enExample)
MY (1) MY160353A (enExample)
NZ (1) NZ602698A (enExample)
PE (1) PE20130524A1 (enExample)
PH (1) PH12012501944A1 (enExample)
PL (1) PL2552404T3 (enExample)
PT (1) PT2552404E (enExample)
RS (1) RS53876B1 (enExample)
SG (1) SG184111A1 (enExample)
SI (1) SI2552404T1 (enExample)
TN (1) TN2012000468A1 (enExample)
TW (2) TW201632184A (enExample)
UA (1) UA109655C2 (enExample)
UY (1) UY33303A (enExample)
WO (1) WO2011120925A1 (enExample)
ZA (1) ZA201206869B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
CN107850568A (zh) * 2015-05-27 2018-03-27 奎斯特诊断投资有限公司 用于质谱定量由微量取样装置提取的分析物的方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN108430453B (zh) * 2015-12-21 2023-03-17 拜耳股份有限公司 制造药物递送装置的方法和根据该方法制成的药物递送装置
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
CN109248166A (zh) * 2017-07-13 2019-01-22 国家卫生计生委科学技术研究所 阿那曲唑储库型阴道环的制备及应用
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions
US20230263724A1 (en) * 2022-02-22 2023-08-24 Celanese Eva Performance Polymers Llc Intravaginal Ring Device for the Delivery of Aromatase Inhibitor
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
FI20000572A7 (fi) * 2000-03-13 2001-09-14 Schering Oy Implantaattien asettamiseen tarkoitettu laite
WO2002072106A2 (en) * 2001-01-26 2002-09-19 Pharmacia Italia Spa Combined method for treating hormono-dependent disorders with exemestane
GB0120147D0 (en) 2001-08-17 2001-10-10 Metris Therapeutics Ltd Treatment method
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
GB0320238D0 (en) * 2003-08-29 2003-10-01 Medical Res Council Treatment of disease
US20050101579A1 (en) * 2003-11-06 2005-05-12 Shippen Eugene R. Endometriosis treatment protocol
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
US20110033519A1 (en) * 2009-08-07 2011-02-10 Leong Madeline Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use

Also Published As

Publication number Publication date
CR20120493A (es) 2012-11-22
GT201200267A (es) 2014-06-04
JP2013523683A (ja) 2013-06-17
DE102010003494A1 (de) 2011-10-06
PH12012501944A1 (en) 2017-01-06
MA34099B1 (fr) 2013-03-05
HRP20150294T1 (hr) 2015-06-19
AU2011234587A1 (en) 2012-10-25
CN103002873B (zh) 2015-02-18
CU20120145A7 (es) 2013-05-31
TWI576107B (zh) 2017-04-01
US20130131027A1 (en) 2013-05-23
TW201632184A (zh) 2016-09-16
PT2552404E (pt) 2015-03-30
TN2012000468A1 (en) 2014-01-30
EP2552404B1 (de) 2015-01-21
EA025582B1 (ru) 2017-01-30
TW201201799A (en) 2012-01-16
NZ602698A (en) 2014-08-29
DK2552404T3 (en) 2015-03-30
PL2552404T3 (pl) 2015-05-29
WO2011120925A1 (de) 2011-10-06
CN103002873A (zh) 2013-03-27
CL2012002722A1 (es) 2013-01-18
AU2011234587B2 (en) 2015-07-09
BR112012024739A2 (pt) 2016-06-07
SI2552404T1 (sl) 2015-04-30
HK1179531A1 (en) 2013-10-04
EP2552404A1 (de) 2013-02-06
UA109655C2 (uk) 2015-09-25
CY1116187T1 (el) 2017-02-08
ES2533101T3 (es) 2015-04-07
KR20130010047A (ko) 2013-01-24
AR080861A1 (es) 2012-05-16
SG184111A1 (en) 2012-10-30
UY33303A (es) 2011-10-31
MY160353A (en) 2017-02-28
ZA201206869B (en) 2016-01-27
CO6630125A2 (es) 2013-03-01
DOP2012000255A (es) 2013-04-30
IL222056A (en) 2016-03-31
JP6012048B2 (ja) 2016-10-25
ME02159B (me) 2015-10-20
CA2794790A1 (en) 2011-10-06
JP2016164200A (ja) 2016-09-08
EA201201358A1 (ru) 2013-04-30
MX2012011329A (es) 2012-11-30
PE20130524A1 (es) 2013-04-26
RS53876B1 (sr) 2015-08-31
US20150359802A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
ECSP12012176A (es) Forma farmacéutica parenteral, que libera inhibidores de aromatasa y gestágenos para el tratamiento de endometriosis
CY2021031I2 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
IL267681A (en) Selective grp94 inhibitors and their uses
EP2780299A4 (en) FUNCTION MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
CL2015000450A1 (es) Métodos y composiciones para el tratamiento de una afección genética
ZA201704192B (en) Acc inhibitors and uses thereof
BR112015001838A2 (pt) composições de inibidor de efluxo e métodos de tratamento utilizando o mesmo.
CO6791602A2 (es) Métodos y sistemas para el tratamiento de pozos
CO6821886A2 (es) Inhibidores potentes y selectivos de nav1.3 y nav1.7
EP2922877A4 (en) IMPROVED PEPTIDATE MEDICINES
BR112013025761A2 (pt) inibidores de hsp90
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
DK2812341T3 (da) C-terminale hsp90-inhibitorer
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
IL228666A (en) Pharmaceuticals for the prevention and / or treatment of HIV in humans
PL2923011T3 (pl) Kombinacja zawierająca kotwę do elementów konstrukcyjnych w kształcie płyty i układ mocujący
CO6990712A2 (es) Combinación farmacéutica antineuritica y composiciones
PL2744601T3 (pl) Sposób i instalacja do obróbki przedmiotów
ES2859675T8 (es) Sensor y procedimiento para operar el sensor
EP2752460A4 (en) MOLDING MATERIAL AND MOLDED BODY USING THE SAME
ZA201307390B (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
ITMI20100187U1 (it) Eurobox - portamonete -contamonete per 1 euro e 2 euro
ES1075150Y (es) Dispositivo para el montaje de estaterias y otros muebles
PL395644A1 (pl) Weryfikacja profilaktyki górniczej i sposób wykonywania profilaktyki górniczej